Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Pegylated liposomal doxorubicin beneficial in metastatic breast cancer

16.09.2008
For women with metastatic breast cancer, treatment with an encapsulated form of the drug doxorubicin offers a well-tolerated option for maintenance therapy that delays progression and offers benefits in terms of survival, new results show.

Spanish researchers led by Dr. Emilio Alba have been studying the effects of pegylated liposomal doxorubicin in a group of 155 women who had already been treated with chemotherapy.

At the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm, they present long-term follow-up data showing that 81% of patients prescribed the drug were alive after one year, compared to 66% of those who did not receive the treatment.

The aim of the therapy was to delay progression of disease while inflicting as few side-effects as possible, said Dr. Alba.

“Despite major advances in adjuvant therapy, the number of patients with metastatic breast cancer who are expected to relapse is substantial,” he said. “In this setting the treatment is not curative, but it is important to explore all the available alternatives.”

“In the case of chemotherapy, toxicity is the main drawback. Almost all studies carried out up to now associate maintenance therapy with a longer time-to-progression, and sometimes more overall survival. However, dealing with toxicity forces us to balance benefits and risks.”

“The main finding of this trial was the low toxicity profile of pegylated liposomal doxorubicin at a dose of 40mg/m2. This dose presented no gastrointestinal toxicity, no grade IV alopecia, and grade IV adverse effects such as mucositis or hand-and-foot syndrome (HFS) were lower than 5%. The treatment also presented no cardiotoxicity. The subjective tolerance was very good.”

Women treated with the drug saw a mean increase in time-to-progression of 3.4 months, the researchers found, which is similar to that of new targeted drugs such as trastuzumab or lapanitib. “While a month would probably fall short, a recent survey indicated 51% of oncologists would consider a time-to-progression increase of 3 months as successful,” Dr. Alba said.

“Maintenance therapy is a good option for almost everybody, if we can design effective treatments associated with a good toxicity profile. I think this goal is achieved in the case of pegylated liposomal doxorubicin,” he said.

Vanessa Pavinato | alfa
Further information:
http://www.esmo.org

More articles from Health and Medicine:

nachricht Spanish scientists create a 3-D bioprinter to print human skin
24.01.2017 | Carlos III University of Madrid

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists spin artificial silk from whey protein

X-ray study throws light on key process for production

A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Breaking the optical bandwidth record of stable pulsed lasers

24.01.2017 | Physics and Astronomy

Choreographing the microRNA-target dance

24.01.2017 | Life Sciences

Spanish scientists create a 3-D bioprinter to print human skin

24.01.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>